Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets.

Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2019 Dec;176 Suppl 1:S1-S20. doi: 10.1111/bph.14747.

2.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors.

Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2019 Dec;176 Suppl 1:S247-S296. doi: 10.1111/bph.14751.

3.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2019 Dec;176 Suppl 1:S297-S396. doi: 10.1111/bph.14752.

4.

Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD.

Singer E, Walter C, Fabbro D, Rageot D, Beaufils F, Wymann MP, Rischert N, Riess O, Hillmann P, Nguyen HP.

Neuropharmacology. 2019 Oct 14;162:107812. doi: 10.1016/j.neuropharm.2019.107812. [Epub ahead of print]

PMID:
31622602
5.

Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.

Borsari C, Rageot D, Beaufils F, Bohnacker T, Keles E, Buslov I, Melone A, Sele AM, Hebeisen P, Fabbro D, Hillmann P, Wymann MP.

ACS Med Chem Lett. 2019 Sep 3;10(10):1473-1479. doi: 10.1021/acsmedchemlett.9b00333. eCollection 2019 Oct 10.

6.

Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.

Von Achenbach C, Weller M, Kaulich K, Gramatzki D, Zacher A, Fabbro D, Reifenberger G, Szabó E.

J Neurochem. 2019 Oct 16. doi: 10.1111/jnc.14899. [Epub ahead of print]

PMID:
31618458
7.

Prostate Cancer Recurrence in Kidney Transplant Recipient 15 Years After Radical Prostatectomy: A Case Report.

Sforza D, Parente A, Pellicciaro M, Morabito M, Iaria G, Anselmo A, Lindfors ER, Corrado F, Cacciatore C, Del Fabbro D, Ingrosso G, Tisone G.

Transplant Proc. 2019 Nov;51(9):2995-2997. doi: 10.1016/j.transproceed.2019.04.098. Epub 2019 Oct 10.

PMID:
31607619
8.

Oncological outcome of R1 vascular margin for mass-forming cholangiocarcinoma. A single center observational cohort analysis.

Torzilli G, Viganò L, Fontana A, Procopio F, Terrone A, Cimino MM, Donadon M, Del Fabbro D.

HPB (Oxford). 2019 Sep 14. pii: S1365-182X(19)30707-5. doi: 10.1016/j.hpb.2019.08.015. [Epub ahead of print]

PMID:
31530450
9.

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.

Borsari C, Rageot D, Dall'Asen A, Bohnacker T, Melone A, Sele AM, Jackson E, Langlois JB, Beaufils F, Hebeisen P, Fabbro D, Hillmann P, Wymann MP.

J Med Chem. 2019 Sep 26;62(18):8609-8630. doi: 10.1021/acs.jmedchem.9b00972. Epub 2019 Sep 11.

PMID:
31465220
10.

(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.

Rageot D, Bohnacker T, Keles E, McPhail JA, Hoffmann RM, Melone A, Borsari C, Sriramaratnam R, Sele AM, Beaufils F, Hebeisen P, Fabbro D, Hillmann P, Burke JE, Wymann MP.

J Med Chem. 2019 Jul 11;62(13):6241-6261. doi: 10.1021/acs.jmedchem.9b00525. Epub 2019 Jun 20.

PMID:
31244112
11.

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.

Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beaufils F, Zucca E, Stathis A, Wymann MP, Cmiljanovic V, Fabbro D, Bertoni F.

Cancers (Basel). 2019 Jun 4;11(6). pii: E775. doi: 10.3390/cancers11060775.

12.

Temperament and character influence on depression treatment outcome.

Balestri M, Porcelli S, Souery D, Kasper S, Dikeos D, Ferentinos P, Papadimitriou GN, Rujescu D, Martinotti G, Nicola MD, Janiri L, Caletti E, Mandolini GM, Pigoni A, Paoli RA, Lazzaretti M, Brambilla P, Sala M, Abbiati V, Bellani M, Perlini C, Rossetti MG, Piccin S, Bonivento C, Fabbro D, Damante G, Ferrari C, Rossi R, Pedrini L, Benedetti F, Montgomery S, Zohar J, Mendlewicz J, Serretti A.

J Affect Disord. 2019 Jun 1;252:464-474. doi: 10.1016/j.jad.2019.04.031. Epub 2019 Apr 9.

PMID:
31005789
13.

Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?

Donadon M, Fontana A, Procopio F, Del Fabbro D, Cimino M, Viganò L, Palmisano A, Torzilli G.

Updates Surg. 2019 Mar;71(1):57-66. doi: 10.1007/s13304-019-00626-3. Epub 2019 Mar 9.

PMID:
30852806
14.

Is R1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients.

Donadon M, Terrone A, Procopio F, Cimino M, Palmisano A, Viganò L, Del Fabbro D, Di Tommaso L, Torzilli G.

Surgery. 2019 May;165(5):897-904. doi: 10.1016/j.surg.2018.12.002. Epub 2019 Jan 26.

PMID:
30691871
15.

Multi-institutional Evaluation of Producing and Testing a Novel 3D-Printed Laparoscopic Trainer.

Parkhomenko E, Yoon R, Okhunov Z, Patel RM, Dolan B, Kaler K, Schwartz MJ, Shah PH, Bierwiler H, Gamboa AJ, Miano R, Germani S, Fabbro DD, Zordani A, Micali S, Kavoussi LR, Clayman RV, Landman J.

Urology. 2019 Feb;124:297-301. doi: 10.1016/j.urology.2018.06.034. Epub 2018 Nov 9.

PMID:
30419263
16.

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.

Rageot D, Bohnacker T, Melone A, Langlois JB, Borsari C, Hillmann P, Sele AM, Beaufils F, Zvelebil M, Hebeisen P, Löscher W, Burke J, Fabbro D, Wymann MP.

J Med Chem. 2018 Nov 21;61(22):10084-10105. doi: 10.1021/acs.jmedchem.8b01262. Epub 2018 Nov 14.

PMID:
30359003
17.

Author Correction: Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinase.

Kreamer NNK, Chopra R, Caughlan RE, Fabbro D, Fang E, Gee P, Hunt I, Li M, Leon BC, Muller L, Vash B, Woods AL, Stams T, Dean CR, Uehara T.

Sci Rep. 2018 Oct 23;8(1):15907. doi: 10.1038/s41598-018-34070-x.

18.

Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinase.

Kreamer NNK, Chopra R, Caughlan RE, Fabbro D, Fang E, Gee P, Hunt I, Li M, Leon BC, Muller L, Vash B, Woods AL, Stams T, Dean CR, Uehara T.

Sci Rep. 2018 Sep 20;8(1):14124. doi: 10.1038/s41598-018-32379-1. Erratum in: Sci Rep. 2018 Oct 23;8(1):15907.

19.

Oncologic superiority of anatomic resection of hepatocellular carcinoma by ultrasound-guided compression of the portal tributaries compared with nonanatomic resection: An analysis of patients matched for tumor characteristics and liver function.

Viganò L, Procopio F, Mimmo A, Donadon M, Terrone A, Cimino M, Fabbro DD, Torzilli G.

Surgery. 2018 Nov;164(5):1006-1013. doi: 10.1016/j.surg.2018.06.030. Epub 2018 Sep 5.

PMID:
30195402
20.

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pellé X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P.

J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7.

PMID:
30137981
21.

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.

Brandt C, Hillmann P, Noack A, Römermann K, Öhler LA, Rageot D, Beaufils F, Melone A, Sele AM, Wymann MP, Fabbro D, Löscher W.

Neuropharmacology. 2018 Sep 15;140:107-120. doi: 10.1016/j.neuropharm.2018.08.002. Epub 2018 Aug 3.

PMID:
30081001
22.

Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants.

Porcelli S, Marsano A, Caletti E, Sala M, Abbiati V, Bellani M, Perlini C, Rossetti MG, Mandolini GM, Pigoni A, Paoli RA, Piccin S, Lazzaretti M, Fabbro D, Damante G, Bonivento C, Ferrari C, Rossi R, Pedrini L, Serretti A, Brambilla P; GECOBIP Group.

Neuropsychobiology. 2017;76(4):209-221. doi: 10.1159/000490955. Epub 2018 Jul 24.

PMID:
30041166
23.

R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management.

Viganò L, Costa G, Cimino MM, Procopio F, Donadon M, Del Fabbro D, Belghiti J, Kokudo N, Makuuchi M, Vauthey JN, Torzilli G.

J Gastrointest Surg. 2018 Oct;22(10):1752-1763. doi: 10.1007/s11605-018-3820-z. Epub 2018 Jun 8.

PMID:
29948554
24.

Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data.

Sguassero Y, Roberts KN, Harvey GB, Comandé D, Ciapponi A, Cuesta CB, Aguiar C, Castro AM, Danesi E, de Andrade AL, de Lana M, Escribà JM, Fabbro DL, Fernandes CD, Flores-Chávez M, Hasslocher-Moreno AM, Jackson Y, Lacunza CD, Machado-de-Assis GF, Maldonado M, Meira WSF, Molina I, Monje-Rumi MM, Muñoz-San Martín C, Murcia L, Nery de Castro C, Sánchez Negrette O, Segovia M, Silveira CAN, Solari A, Steindel M, Streiger ML, Vera de Bilbao N, Zulantay I, Sosa-Estani S.

Int J Infect Dis. 2018 Aug;73:93-101. doi: 10.1016/j.ijid.2018.05.019. Epub 2018 Jun 4. Review.

25.

Reply to: Surgical treatment of metachronous rectal liver and lung metastases: A combined videolaparoscopic and videothoracoscopic approach.

Del Fabbro D, Torzilli G.

Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):282. doi: 10.1016/j.hbpd.2018.03.012. Epub 2018 Mar 24. No abstract available.

PMID:
29691136
26.

Hepatectomy with or without the thoraco-abdominal approach: impact on perioperative outcome.

Donadon M, Mimmo A, Cosola D, Terrone A, Procopio F, Del Fabbro D, Cimino M, Viganò L, Torzilli G.

HPB (Oxford). 2018 Aug;20(8):752-758. doi: 10.1016/j.hpb.2018.02.639. Epub 2018 Mar 31.

27.

Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?

Vigano L, Darwish SS, Rimassa L, Cimino M, Carnaghi C, Donadon M, Procopio F, Personeni N, Del Fabbro D, Santoro A, Torzilli G.

Ann Surg Oncol. 2018 Jun;25(6):1676-1685. doi: 10.1245/s10434-018-6387-8. Epub 2018 Feb 27.

PMID:
29488188
28.

Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Viganò L, Pedicini V, Comito T, Carnaghi C, Costa G, Poretti D, Franzese C, Personeni N, Del Fabbro D, Rimassa L, Scorsetti M, Santoro A, Solbiati L, Torzilli G.

World J Surg. 2018 Aug;42(8):2651-2659. doi: 10.1007/s00268-018-4525-x.

PMID:
29423737
29.

Hepatic vein management in a parenchyma-sparing policy for resecting colorectal liver metastases at the caval confluence.

Torzilli G, Procopio F, Viganò L, Cimino M, Costa G, Del Fabbro D, Donadon M.

Surgery. 2018 Feb;163(2):277-284. doi: 10.1016/j.surg.2017.09.003. Epub 2017 Nov 21.

PMID:
29169612
30.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA; NC-IUPHAR.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.

31.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

32.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.

Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16. doi: 10.1111/bph.13882.

33.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors.

Alexander SP, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S225-S271. doi: 10.1111/bph.13876.

34.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Alexander SP, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359. doi: 10.1111/bph.13877.

35.

The Liver Tunnel: Intention-to-treat Validation of a New Type of Hepatectomy.

Torzilli G, Procopio F, Viganò L, Costa G, Fontana A, Cimino M, Donadon M, Del Fabbro D.

Ann Surg. 2019 Feb;269(2):331-336. doi: 10.1097/SLA.0000000000002509.

PMID:
28902667
36.

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, Jackson E, Zhang X, Sele A, Borsari C, Mestan J, Hebeisen P, Hillmann P, Giese B, Zvelebil M, Fabbro D, Williams RL, Rageot D, Wymann MP.

J Med Chem. 2017 Sep 14;60(17):7524-7538. doi: 10.1021/acs.jmedchem.7b00930. Epub 2017 Sep 1.

37.

Individualized risk estimation for postoperative morbidity after hepatectomy: the Humanitas score.

Donadon M, Fontana A, Palmisano A, Viganò L, Procopio F, Cimino M, Del Fabbro D, Torzilli G.

HPB (Oxford). 2017 Oct;19(10):910-918. doi: 10.1016/j.hpb.2017.06.009. Epub 2017 Jul 22.

38.

Sexual health, adherence to Mediterranean diet, body weight, physical activity and mental state: factors correlated to each other.

Della Camera PA, Morselli S, Cito G, Tasso G, Cocci A, Laruccia N, Travaglini F, Del Fabbro D, Mottola AR, Gacci M, Serni S, Carini M, Natali A.

Urologia. 2017 Oct 25;84(4):221-225. doi: 10.5301/uj.5000255. Epub 2017 Jul 14.

PMID:
28731489
39.

Twelve-year experience of "radical but conservative" liver surgery for colorectal metastases: impact on surgical practice and oncologic efficacy.

Torzilli G, Viganò L, Gatti A, Costa G, Cimino M, Procopio F, Donadon M, Del Fabbro D.

HPB (Oxford). 2017 Sep;19(9):775-784. doi: 10.1016/j.hpb.2017.05.006. Epub 2017 Jun 16.

40.

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.

Bohnacker T, Prota AE, Beaufils F, Burke JE, Melone A, Inglis AJ, Rageot D, Sele AM, Cmiljanovic V, Cmiljanovic N, Bargsten K, Aher A, Akhmanova A, Díaz JF, Fabbro D, Zvelebil M, Williams RL, Steinmetz MO, Wymann MP.

Nat Commun. 2017 Mar 9;8:14683. doi: 10.1038/ncomms14683.

41.

Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation.

Filipenko I, Schwalm S, Reali L, Pfeilschifter J, Fabbro D, Huwiler A, Zangemeister-Wittke U.

Biochim Biophys Acta. 2016 Nov;1861(11):1840-1851. doi: 10.1016/j.bbalip.2016.09.005. Epub 2016 Sep 9.

PMID:
27616330
42.

Simple methodology to directly genotype Trypanosoma cruzi discrete typing units in single and mixed infections from human blood samples.

Bontempi IA, Bizai ML, Ortiz S, Manattini S, Fabbro D, Solari A, Diez C.

Infect Genet Evol. 2016 Sep;43:123-9. doi: 10.1016/j.meegid.2016.05.026. Epub 2016 May 18.

PMID:
27208806
43.

Surgical treatment of synchronous colorectal liver and lung metastases: the usefulness of thoracophrenolaparotomy for single stage resection.

Del Fabbro D, Alloisio M, Procopio F, Cimino M, Donadon M, Palmisano A, Vigano L, Torzilli G.

Hepatobiliary Pancreat Dis Int. 2016 Apr;15(2):216-9.

PMID:
27020639
44.

Immunoglobulin K light chain deficiency: A rare, but probably underestimated, humoral immune defect.

Sala P, Colatutto A, Fabbro D, Mariuzzi L, Marzinotto S, Toffoletto B, Perosa AR, Damante G.

Eur J Med Genet. 2016 Apr;59(4):219-22. doi: 10.1016/j.ejmg.2016.02.003. Epub 2016 Feb 4.

PMID:
26853951
45.

Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort.

Viganò L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G.

Ann Surg Oncol. 2016 Apr;23(4):1352-60. doi: 10.1245/s10434-015-5009-y. Epub 2015 Dec 29.

PMID:
26714946
46.

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):6024-109. doi: 10.1111/bph.13354.

47.

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors.

Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):5979-6023. doi: 10.1111/bph.13353.

48.

The Concise Guide to PHARMACOLOGY 2015/16: Overview.

Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):5729-43. doi: 10.1111/bph.13347.

49.

Phosphorylation, Signaling, and Cancer: Targets and Targeting.

Marmiroli S, Fabbro D, Miyata Y, Pierobon M, Ruzzene M.

Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21. No abstract available.

50.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Spedding M, Catterall WA, Fabbro D, Davies JA; NC-IUPHAR.

Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.

Supplemental Content

Loading ...
Support Center